Amryt Reports Strong Q3 2021 Results

~ 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY excluding the impact of sporadic LATAM orders ~ 7th consecutive quarter of positive EBITDA generation excluding Chiasma transaction costs ~ Cash of $123.2M at September 30, 2021 ~ Reaffirming FY 2021 revenue guidance to $220M - $225M, representing 20-23% YoY growth

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here